Last reviewed · How we verify
Ciprofloxacin plus metronidazole
Ciprofloxacin plus metronidazole, marketed by Facultad Nacional de Salud Publica, is a combination therapy currently available in the market. The key composition patent for this drug is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Ciprofloxacin plus metronidazole |
|---|---|
| Also known as | ciprofloxacino, metronidazole benzoato |
| Sponsor | Facultad Nacional de Salud Publica |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment (NA)
- Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer (PHASE2)
- Combination Study of Antibiotics With Enzalutamide (PROMIZE) (PHASE1, PHASE2)
- Evaluation of Different Medicaments in the Management of Necrotic Primary Molars by Lesion Sterilization and Tissue Repair (NA)
- A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis (PHASE3)
- Effect of Intracanal Medicaments on Post-Operative Pain in Symptomatic Apical Periodontitis: An RCT (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciprofloxacin plus metronidazole CI brief — competitive landscape report
- Ciprofloxacin plus metronidazole updates RSS · CI watch RSS
- Facultad Nacional de Salud Publica portfolio CI